Friday, November 16, 2012

The smaller the tumor, the better your chances

The odds of surviving cancer of the pancreas increase dramatically for patients whose tumors are smallest, as per a new study by scientists at Saint Louis University and the M.D. Anderson Cancer Center in Houston the first study to specifically evaluate the link between tumor size and survival rates for one of the most common and deadly cancers.

The findings in the current edition of Pancreas (www.pancreasjournal.com) vividly underscore the importance of early diagnosis of pancreas cancer, the scientists said.
The smaller the tumor, the better your chances
Even though it seems intuitive and was supported by preliminary observations from earlier studies, for the first time we now have evidence that a progressive decrease in the size of a pancreatic tumor at the time of diagnosis improves patient outcomes rather dramatically, said Banke Agarwal, M.D., Associate Professor of gastroenterology at the Saint Louis University School of Medicine and lead author of the study.

These data emphasize the benefit and the need of finding and diagnosing tumors in the pancreas as early as possible, Agarwal added. In order to make progress against pancreas cancer, we have to redouble our efforts to identify symptoms that are linked to the early stages of the disease.

Pancreas cancer is the fourth most common cancer in the United States and one of the most deadly, responsible for more than 33,000 deaths a year, as per the National Institutes of Health.

Despite a number of advances in the fight against other cancers in recent years, the prognosis for patients diagnosed with the pancreas cancer has remained extremely poor. Thats largely because the cancer is frequently not suspected and is difficult to diagnose in its early stages, when most people are asymptomatic or have non-specific symptoms that are easily ignored or attributed to other diseases.

The study looked at 65 patients who were diagnosed with pancreas cancer at the M.D. Anderson Cancer in Houston between December 2000 and December 2001. Their average age was 67 years old; 38 were men.

Scientists found a striking connection between a patients prognosis and the size of their tumor at the time of diagnosis.

Of the 12 patients whose tumors were 20 millimeters or smaller, their median survival after diagnosis was 17.2 months. For those with tumors 21-25 mm, median survival was 12.3 months. For those with tumors 26-30 mm, median survival was 8.5 months. And for those with tumors larger than 30 mm, median survival was 7.6 months. Of those patients whose tumors were 20 mm or smaller, two were still alive after 48 months; none of the patients with tumors larger than 30 mm were alive after 36 months.

Unfortunately, while the patients with the smallest tumors had the highest rates of survival, they were relatively small in number. Only 12 patients or 18 percent had tumors 20 mm or smaller. By contrast, the largest group of patients 27, or 42 percent had tumors larger than 30 mm.

In addition, the average tumor size of patients in the study was 32.9 mm well above the threshold at which survival rates are lowest. That figure is roughly comparable to an average tumor size of about 30 mm among pancreas cancer patients in general, as per the study.

These numbers illustrate why weve made so little progress in improving outcomes for people who are diagnosed with pancreas cancer were not finding their tumors until theyre too big and its too late, Agarwal said. We know we have a much better chance of helping someone survive pancreas cancer if its caught early and their tumor is small.

Major advances in imaging technology in recent years have greatly improved physicians ability to diagnose progressively smaller pancreatic tumors. This hasnt led to earlier diagnosis, however, because patients generally dont get to the doctor until symptoms appear and by then its too late.

Agarwal said scientists will need to focus on finding ways to identify people who should be screened early for pancreas cancer. Screening of the general population for the disease hasnt proven effective but screening of people with a family history of pancreas cancer is under active investigation, he said.

In addition, preliminary data from other studies have shown that elderly people whove been recently diagnosed with diabetes or depression have a higher likelihood of pancreas cancer providing another avenue for scientists to explore, Agarwal said.

Posted by: Sue    Source


View the original article here

Quality of life once the cancer may depend on the type of Tumor

health day

Certain types leave survivors with worse mental and physical well-being, study findsTuesday, October 30 HealthDay News)-the quality of life of cancer survivors may vary depending on the type of cancer, and millions of United States cancer survivors have a lower quality than normal life, a new study finds.

The researchers looked at more than 1,800 survivors of cancer in adults and more than 24,000 adults without a history of cancer and found that the survivors of cancers of prostate, breast and melanoma a mental - and Fisica-salud - quality of life similar to those who never had cancer.

Survivors of cervical, blood and colorectal cancer as well as cancer survivors with a survival rate of five years of less than 25 per cent (such as liver, lung and pancreatic cancer), however, had worse Fisica-salud - quality of life.

And the survivors of cervical cancer and cancer with a five-year survival rate low also had poorer mental-health-quality of life, according to the study, which was published in the October 30 in the journal Epidemiology, biomarkers & prevention of cancer.

The researchers found that 25 percent of cancer survivors had lower normal Fisica-salud - quality of life, and 10 percent lower than normal mental health quality of life-related. In total, about 3.3 million United States cancer survivors have a physical life quality of below average and nearly 1.4 million have one below the average mental quality of life, the researchers estimated.

"It is very concerning there are a significant number of cancer survivors that years of poor physical or mental health after cancer experience", study author Kathryn Weaver, an Assistant Professor at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, said in a press release from the journal.

"Our results serve as a basis so that in five to 10 years, we can evaluate whether current approaches to improve the health and well-being of cancer survivors are having a positive effect," he said. "I also hope our data will be calling attention to the needs of survivors of cancer, especially those with cervical, blood and less common cancers - and the importance of the supervision of these individuals, even long after his diagnosis of cancer."

More information

The national United States cancer Institute has more about life after cancer treatment.

Source: Cancer Epidemiology, biomarkers & prevention, press release, 30 October 2012

Copyright © 2010 HealthDay. All rights reserved.


View the original article here

Thursday, November 15, 2012

Cancer-Causing Gene Alone Doesn't Trigger Pancreatic Cancer, Mayo-Led Study Finds

Main Category: Pancreatic Cancer
Also Included In: Cancer / Oncology;  Genetics
Article Date: 12 Sep 2012 - 1:00 PDT Current ratings for:
Cancer-Causing Gene Alone Doesn't Trigger Pancreatic Cancer, Mayo-Led Study Finds
not yet rated4 and a half stars
More than a cancer-causing gene is needed to trigger pancreatic cancer, a study led by Mayo Clinic has found. A second factor creates a "perfect storm" that allows tumors to form, the researchers say. The study, published in the Sept. 10 issue of Cancer Cell, overturns the current belief that a mutation in the KRAS oncogene is enough to initiate pancreatic cancer and unrestrained cell growth.

The findings uncover critical clues on how pancreatic cancer develops and why few patients benefit from current therapies. The findings also provide ideas about how to improve treatment and prevention of pancreatic cancer.

The research team, led by Howard C. Crawford, Ph.D., a cancer biologist at Mayo Clinic's campus in Florida, and Jens Siveke, M.D., at Technical University in Munich, Germany, found that for pancreatic cancer to form, mutated KRAS must recruit a second player: the epidermal growth factor receptor, or EGFR.A third genetic participant known as Trp53 makes pancreatic tumors very difficult to treat, the study showed.

The scientists also found that EGFR was required in pancreatic cancer initiated by pancreatic inflammation known as pancreatitis.

"We believe the perfect storm needed to trigger pancreatic cancer include KRAS mutations and inflammation in the organ, which then work synergistically to turn on EGFR," says Dr. Crawford.

"The bottom line is, without EGFR, tumors don't form - and that was never known before this study," he says. "We also think that inflammation in the pancreas has a big impact on turning on EGFR."

The researchers discovered that when they blocked EGFR activity, the mice studied were protected against developing chronic pancreatitis and pancreatic cancer.

They further found that in mice that had lost expression of the TP53 tumor suppressor - a situation that mirrors up to 60 percent of human pancreatic cancer cases - tumors escape the dependency on EGFR for initiation and continued growth of pancreatic cancer, Dr. Crawford says.

Pancreatic cancer is a highly lethal disease; no drug has been able to target the mutant KRAS protein. The study suggests some patients, such as those with chronic pancreatitis, may be good candidates for treatment with EGFR inhibitors to fight or prevent pancreatic cancer, Dr. Crawford says.

"The clinical implications of this study are exciting. It suggests that pancreatic cancer patients with normal p53 activity, as well as patients with chronic pancreatitis, may be good candidates for treatment with EGFR inhibitors," Dr. Crawford says.

The EGFR inhibitor erlotinib is part of the standard therapy for pancreatic cancer patients, but has minimal effects in the patient population as a whole, he adds. "But that may be because many of the patients likely had a mutation in the TRP53 tumor suppressor, so erlotinib would not help them, since EGFR was no longer necessary for tumor growth.

"Perhaps erlotinib or other EGFR inhibitors would work much better in patients who do not have a TRP53 mutation," he says. "We also believe this kind of drug could prevent pancreatic cancer formation in patients with chronic pancreatitis, which is a significant risk factor for development of pancreatic tumors."

"These findings give us some greatly needed clues about how pancreatic cancer develops and progresses," Dr. Crawford says. "The more we understand about these early tumors, the more we will be able to work on diagnosis and therapy."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our pancreatic cancer section for the latest news on this subject. The study was funded by the National Cancer Institute.

Mayo Clinic

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Cancer-Causing Gene Alone Doesn't Trigger Pancreatic Cancer, Mayo-Led Study Finds." Medical News Today. MediLexicon, Intl., 12 Sep. 2012. Web.
12 Nov. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Cancer-Causing Gene Alone Doesn't Trigger Pancreatic Cancer, Mayo-Led Study Finds'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Wednesday, November 14, 2012

Oral Bacteria Might Signal Early Pancreatic Cancer

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Simple 'spit' test might someday help screen for disease, small study suggests


View the original article here

New Pathway Revealed By Genome Analysis Of Pancreas Tumors

Main Category: Pancreatic Cancer
Also Included In: Genetics
Article Date: 26 Oct 2012 - 0:00 PDT Current ratings for:
New Pathway Revealed By Genome Analysis Of Pancreas Tumors
4 stars4 stars
A Baylor College of Medicine physician-scientist was part of the local team that took part in the international effort. A report appears online in the journal Nature.

"We now know every gene involved in pancreatic cancer," said Dr. William Fisher, professor of surgery and director of the Elkins Pancreas Center at BCM. "This study ushers in a whole new era of taking care of patients with pancreatic cancer. We will look back on this as a turning point in understanding and treating this disease."

The study follows a five-year collaboration between the Michael E. DeBakey Department of Surgery and the Baylor College of Medicine Human Genome Sequencing Center, said Fisher.

The Baylor College of Medicine Human Genome Sequencing Center was one of three sequencing centers worldwide that analyzed the genomes of pancreatic tumors and normal tissues taken from 142 patients with the disease. The BCM center, along with the Australian Pancreatic Center Genome Initiative and the Ontario Institute for Cancer Research Pancreatic Cancer Genome Study carried out detailed studies on 99 of the tumors, identifying 1982 mutations that resulted in a change to a protein and 1,628 significant copy number variations events in which the structure of the chromosomes themselves are changed, either deleting or duplicating genetic information.

The multi-institution, international consortium of researchers discovered mutations in genes involved in chromatin modification (changes that affect the way DNA is packaged inside the cell) and axon guidance (the process by which the axon - a long threadlike project that carries impulses away from the neuron - is guided to grow to its proper target).

"This is a category of genes not previously linked to pancreatic cancer," said Fisher. "We are poised to jump on this gene list and do some exciting things."

New information is much welcome in the field of pancreatic cancer, which is the fourth leading cause of cancer death with an overall five-year survival rate of less than 5 percent. The figures have not changed substantially in the past 50 years.

The study is the first to report findings from primary tumors in the disease. Previously only cell lines or tumors transplanted into mice had been used because the tumors are so small. "Therefore it required new techniques to sensitively identify mutations that were important to the development of cancer," said Dr. David Wheeler, associate professor in the BCM Human Genome Sequencing Center who oversees the center's cancer projects. Wheeler and Fisher are also members of the NCI-designated Dan L. Duncan Cancer Center at BCM.

Wheeler pointed out that large, multi-centered studies using well- annotated groups of patients with cancer are pivotal to studies such as this, which promise to guide the way toward developing new treatment strategies.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our pancreatic cancer section for the latest news on this subject. Other BCM people who took part include Marie-Claude Gingras, Nipun Kakkar, Fengmei Zhao, Yuan Qing Wu, Min Wang, Donna M. Muzny, Sally E. Hodges, Jennifer Drummond, Kyle Chang, Yi Han, Lora Lewis, Huyen Dinh and Christian Buhay, as well as Dr. Richard A. Gibbs, director of the BCM Human Genome Sequencing Center.
Funding for this work came from; the National Health and Medical Research Council of Australia; the Department of Innovation, Industry, Science and Research of Australia; the Australian Cancer Research Foundation; the Queensland Government, the Cancer Council New South Wales; the Avner Nahmi Pancreatic Cancer Research Foundation; the R.T. Hall Trust; the American Association of Cancer Research; Landon Foundation; the RACS; the BCM Human Genome Sequencing Center National Human Genome Research Institute grant; the Cancer Prevention and Research Institute of Texas; The Ontario Institute for Cancer Research; The Ontario Ministry of Economic Development and Innovation and the Canada Foundation for Innovation.
Baylor College of Medicine Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "New Pathway Revealed By Genome Analysis Of Pancreas Tumors." Medical News Today. MediLexicon, Intl., 26 Oct. 2012. Web.
12 Nov. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'New Pathway Revealed By Genome Analysis Of Pancreas Tumors'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, November 13, 2012

Lives Could Be Saved By Referring Cancer Patients To More Experienced And Successful Hospitals For Surgery

Main Category: Pancreatic Cancer
Also Included In: Public Health;  Colorectal Cancer
Article Date: 21 Oct 2012 - 0:00 PDT Current ratings for:
Lives Could Be Saved By Referring Cancer Patients To More Experienced And Successful Hospitals For Surgery
4 starsnot yet rated
Researchers at Rice University report that referring cancer patients to hospitals with better track records for surgery could save lives and not raise the cost to patients. The study was reported online in the journal Forum for Health Economics and Policy.

The researchers reviewed data on two cancer operations that are at "opposite ends of the spectrum" - colon and pancreatic resections, said paper author Vivian Ho, Rice University's Baker Institute Chair in Health Economics and a professor of economics. Pancreatic resection is performed much less often than colon resection, but it's a very complicated operation that can take 5 to 8 hours and has a much higher mortality rate. Colon resection is more straightforward, is performed much more often and has a much lower mortality rate.

"If all patients needing surgery for colon cancer were referred to hospitals that have consistently achieved mortality rates in the bottom half of all hospitals performing this operation, then the average mortality rate could fall from a rate of 3.8 percent to 2.4 percent," Ho said. "And if all patients who require surgical resection for pancreatic cancer were referred to hospitals performing 11 or more of these operations per year, mortality rates could fall by half, from a rate of 6 percent to 3 percent."

The analysis was based primarily on hospital records for all patients who received surgery for colon cancer or pancreatic cancer in California, Florida, New Jersey or New York between 2001 and 2005. This data was combined with hospital information from the American Hospital Association, the Medicare program and MarketScan Research Data. The researchers used this data to determine the association between the number of surgical operations performed each year and patient mortality rates for each cancer type. Regression analysis was used to adjust for multiple differences in patient characteristics that are important determinants of patient mortality.

The investigators then used their regression analyses to simulate how mortality rates might change if, for instance, patients at poorly performing hospitals were referred to the closest hospital that had achieved mortality rates (adjusted for differences in patient characteristics) in the lower half of the distribution relative to all other hospitals in their state between 2001 and 2005.

For colon cancer patients, higher-volume hospitals did not achieve lower mortality rates than hospitals that performed fewer colon resections per year. However, many hospitals performed consistently better than others in terms of lower patient mortality during the study period, Ho said.

"We were concerned that the centralization of cancer care that would result from referring patients to a smaller set of higher-volume hospitals could give these hospitals additional market power to raise prices," Ho said. "We also wondered whether higher-volume hospitals might have a different cost structure that would raise or lower costs per patient. We found no statistical evidence that hospitals that performed more of these cancer operations were able to charge higher prices to patients for these services. We found that costs per patient were indeed higher for hospitals performing more pancreatic cancer surgery. However, these higher costs were not passed on to patients as higher prices for patient care."

Ho recommended that mechanisms be constructed to refer cancer patients to those hospitals where they are likely to achieve better outcomes. "Some states already post information on their health department's website on the number of pancreatic cancer surgeries performed by each hospital per year, or inpatient mortality rates adjusted for patient characteristics. Private not-for-profit organizations such as the American Cancer Society and the American College of Surgeons could partner with public national and state organizations to replicate the information in our study and make it available to referring physicians and their patients."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our pancreatic cancer section for the latest news on this subject.
The study was supported by a grant from the National Cancer Institute at the National Institutes of Health.

The study, “Can Centralization of Cancer Surgery Improve Social Welfare?”: http://www.degruyter.com/view/j/fhep.2012.15.issue-3/issue-files/fhep.2012.15.issue-3.xml

Rice University

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Lives Could Be Saved By Referring Cancer Patients To More Experienced And Successful Hospitals For Surgery." Medical News Today. MediLexicon, Intl., 21 Oct. 2012. Web.
12 Nov. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Lives Could Be Saved By Referring Cancer Patients To More Experienced And Successful Hospitals For Surgery'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Is that cyst Pancreatic Cancer?

Working with scientists from the University of Michigan and Indiana University, Van Andel Research Institute (VARI) researchers have developed a method that could be used to predict whether pancreatic cysts are non-malignant or are precursors to invasive cancer.

More pancreatic cysts are being detected due to the widespread use of high resolution abdominal imaging. These advances in early detection, when coupled with the new findings, could result in fewer deaths from pancreas cancer, which struck more than 42,000 Americans in 2009 and killed more than 35,000, as per the National Cancer Institute.
Is that cyst Pancreatic Cancer?
"Because of the difficulty in detecting pancreas cancer in its early stages, most cancers are advanced at the time of diagnosis and recur after removal of the tumor," said VARI Senior Scientific Investigator Brian Haab, Ph.D., first author of a study reported in the recent issue of Annals of Surgery. "The best hope for a long-term cure appears to be the detection and removal of these pre-malignant cysts".

"Dr. Haab and colleagues have sought to address a very challenging clinical management problem regarding cystic lesions of the pancreas," said Peter J. Allen, MD, FACS, a doctor and researcher specializing in pancreatic, liver, and stomach cancer at Memorial Sloan-Kettering Cancer Center. "As the use of cross-sectional imaging increases, clinicians are seeing increased numbers of patients with these lesions and it will become imperative to sort out non-malignant from pre-cancerous." .

The most common and deadly form of pancreas cancer, pancreatic ductal adenocarcinomas, develops from three types of cysts. Eventhough the most prevalent type is too small to be detected, the other two can be found using CT or ultrasound imaging and account for 10 - 15% of pancreas cancers. However, current methods can only distinguish pre-malignant cysts from those that are non-malignant with up to 79% accuracy.

Using fluid from a variety of cyst types, scientists looked for patterns in the variations of carbohydrate structures called glycans to determine if there were any biomarkers that could more accurately distinguish between pre-malignant and non-malignant cysts. They found several candidates, some of which could be used in combination to determine cyst type.

"Further study will be needed to validate the clinical value of using glycan variations to differentiate cyst types, but it seems like they are more accurate than current methods," said Dr. Haab.

"(Dr. Haab's) identification of variants of MUC-1, MUC-5AC, and MUC-16 (genes) within the cyst fluid of pre-cancerous lesions is exciting as our current ability to non-operatively define these lesions is limited," said Dr. Allen. "Hopefully with larger numbers of patients these results can be validated and be put into clinical use".

Posted by: Sue    Source


View the original article here